The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease

The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease - the impact of Vildagliptin On daily Glucose profile and coronary plaqUE character in impaired glucose tolerance patients with coronary artery disease:VOGUE-KOBE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008620

Enrollment

Registered

2012-08-06

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with coronary artery disease and impaired glucose tolerance (IGT)

Interventions

Vildagliptin group:start with Vildagliptin 50 mg/day Diet and exercise without DPP-4 inhibitotr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)In patients undergoing PCI, "untreated IGT" and "2-hour plasma/serum glucose level: 140mg/dL to 199mg/dL in a 75g oral glucose tolerance test" 2)LDL-chol < 100mg/dl in patients without statin. LDL-chol < 120mg/dl in patients with statin. 3)patients between 20 and 80 years old 4)Written consent for participation in the study

Exclusion criteria

Exclusion criteria: Patients meeting one of the following conditions will be excluded: 1)under treatment of diabetes, or type 1 diabetes 2)severe liver dysfunction 3)severe renal dysfunction 4)severe heart failure) (NYHA/New York Heart Association stage III or severer) 5)Malignancies or other diseases with poor prognosis 6) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 7) past medical history of hypersensitivity to investigational drugs 8) judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Change in coronary plaque character analyzed by coronary angiography, intravascular ultrasound, and optical coherence tomography, and daily glucose profile analyzed by 24-hour continuous glucose monitoring system before and after 6 months treatment with vildagliptin in comparison with conventional treatment without DPP-4 inhibitor	—

Secondary

Measure	Time frame
1)Changes in the IMT value measured by carotid arterial echography 2)Changes in HbA1c (NGSP) and 75g OGTT (glucose and insulin levels after glucose load)	—

Countries

Japan

Contacts

Public ContactToshiro Shinke

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

shinke@med.kobe-u.ac.jp+81-78-382-5846

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026